Match!
Massimo Loda
Harvard University
546Publications
101H-index
44.9kCitations
Publications 546
Newest
#1David P. Labbé (Harvard University)H-Index: 4
#2Giorgia Zadra (Harvard University)H-Index: 16
Last.Myles Brown (Harvard University)H-Index: 91
view all 34 authors...
Systemic metabolic alterations associated with increased consumption of saturated fat and obesity are linked with increased risk of prostate cancer progression and mortality, but the molecular underpinnings of this association are poorly understood. Here, we demonstrate in a murine prostate cancer model, that high-fat diet (HFD) enhances the MYC transcriptional program through metabolic alterations that favour histone H4K20 hypomethylation at the promoter regions of MYC regulated genes, leading ...
Source
Prostate cancers are considered immunologically ‘cold’ tumors as they have demonstrated poor response to check-point inhibitor therapy (CPI). Recently, enrichment of interferon response genes suggests a favorable response to CPI across various disease sites. The enhancer of zeste homolog-2 (EZH2) is over-expressed in prostate cancer and is known to negatively regulate IFN response genes. Here, we demonstrate that inhibition of EZH2 catalytic activity in prostate cancer models increases expressio...
Source
#1Sheheryar Kabraji (Harvard University)H-Index: 6
Last.Sridhar Ramaswamy (Harvard University)H-Index: 56
view all 7 authors...
Ductal carcinoma in situ (DCIS) of the breast precedes the development of invasive breast cancer and reflects the genomic changes and protein expression profile of invasive disease. AKT1low cancer cells (QCC) are a rare, drug-tolerant, epigenetically plastic, and quiescent cancer cell subset that we previously identified at a frequency of 0.5–1% in primary breast tumors using the marker profile: AKTlow/H3K9me2low/HES1high. Here we used quantitative immunofluorescence microscopy with computationa...
Source
Purpose:Statins are associated with lower risk of aggressive prostate cancer, but lethal prostate cancer is understudied and contributing mechanisms unclear. We prospectively examined statins and lethal prostate cancer risk in the Health Professionals Follow-up Study (HPFS), tested associations with molecular subtypes, and integrated gene expression profiling to identify putative mechanisms. Experimental Design:Our study included 44,126 men cancer-free in 1990, followed for prostate cancer incid...
Source
Source
Summary Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor CREB5 confers enzalutamide resistance in an open reading frame (ORF) expression screen and in tumor xenografts. CREB5 overexpression is essential for an enzalutamide-resistant patient-derived organoid. In AR-expressing prostate cancer cells, CREB...
Source
#1Mariano J. Alvarez (Columbia University)H-Index: 23
#2Pengrong Yan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 17
Last.Andrea CalifanoH-Index: 60
view all 21 authors...
Source
Source
#1Anjali V. SheahanH-Index: 3
#2Katherine L. MorelH-Index: 4
Last.Leigh EllisH-Index: 16
view all 20 authors...
Source
#1Yiwen Zhang (Harvard University)
#2Cindy Ke Zhou (Harvard University)H-Index: 1
Last.Ericka M. Ebot (Harvard University)H-Index: 5
view all 12 authors...
Background: Inflammation and focal atrophy are common features adjacent to prostate tumors. Limited evidence exists on whether these features have prognostic significance. Methods: In the Health Professionals Follow-Up Study and Physicians9 Health Study, we studied 1,035 men diagnosed with prostate cancer. A genitourinary pathologist centrally reviewed tumor and normal areas of hematoxylin and eosin slides from prostate cancer specimens for the presence of acute and chronic inflammation, and fou...
Source
12345678910